News

FDA has approved apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. Combined, DVT and PE are known as VTE.

FDA has approved fluticasone furoate inhalation powder (Arnuity Ellipta, GlaxoSmithKline) for maintenance treatment of asthma in patients aged 12 years and older.

FDA has approved peginterferon beta-1a (Plegridy, Biogen Idec) for the treatment of adults with relapsing forms of multiple sclerosis (MS).

FDA has approved eliglustat (Cerdelga, Genzyme), the only first-line oral therapy for the long-term treatment of adults with the Type 1 form of Gaucher disease.

FDA has approved a new use for bevacizumab (Avastin, Genentech) in combination with chemotherapy for the treatment of patients with aggressive and late-stage cervical cancer.

Not surprisingly, the treatment costs associated with ACS and its various comorbidities are astoundingly high.

Overweight and obese postmenopausal breast cancer patients taking aromatase inhibitors may gain a significant benefit by adding nonsteroidal anti-inflammatory drugs (NSAIDs) to their treatment, according to a study published in the August 14 issue of Cancer Research.

FDA has approved suvorexant (Belsomra, Merck) for adults with insomnia who have difficulty falling asleep and/or staying asleep.

A high-dose influenza vaccine protects the senior population better than the standard-dose influenza vaccine, according to a study published in the August 14 issue of the New England Journal of Medicine.

Patients with advanced liver disease or other severe symptoms of hepatitis C virus (HCV) infection should be first in line for drug therapy, according to a new guideline from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.

Herpes zoster vaccine continues to be effective in protecting older adults against shingles, even after they undergo chemotherapy, a study published August 4 in Clinical Infectious Diseases.

Adaptability and flexibility is and will continue to be the key to both survival and success

The World Health Organization (WHO) has authorized the use of experimental drugs in the Ebola outbreak in West Africa. The death toll has reached 1,000, including a Spanish priest.

The federal government’s cost for Medicare Part D will increase between $2.9 billion and $5.8 billion if we see 15% to 30% of hepatitis C (HCV)-infected beneficiaries receive treatment in 2015 and the cost of treatment averages $84,000, according to a new study by Milliman.

Hospitalization costs for rivaroxaban (Xarelto, Janssen) were significantly lower than warfarin in patients with nonvalvular atrial fibrillation (NVAF), according to a study in the August 2014 issue of Current Medical Research & Opinion.

Widespread anticoagulant undertreatment persists among atrial fibrillation (AFib) patients at high risk of stroke, despite current medical treatment guidelines, which recommend thromboprophylaxis for this patient population unless contraindicated, according to a recent study in BMC Health Services Research.

FDA has approved canagliflozin/metformin (Invokamet, Janssen), the first fixed-dose combination in the class of sodium glucose co-transporter 2 (SGLT2) inhibitors for the treatment of adults with type 2 diabetes.

If 15% to 30% of HCV-infected beneficiaries receive treatment in 2015 with the cost of treatment averaging $84,000, Medicare Part D could increase between $2.9 billion and $5.8 billion

Physicians and patients should avoid new drugs unless they are truly breakthrough drugs, according to a study in Health Affairs.

Community pharmacists can have a significant role in improving an entire patient population’s medication adherence, and its overall health, according to a study published in Health Affairs.

FDA has approved oritavancin (Orbactiv, The Medicines Company) for injection for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible designated Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA).

Hetlioz (tasimelteon) is a melatonin receptor agonist, similar to Rozerem (ramelteon) that was approved by FDA in January 2014 for the treatment of N24HSWS caused by a completely blind person’s inability to regulate their internal clock.

From 2013 to 2022, GPOs are estimated to save Medicare and Medicaid a combined $398.8 billion

FDA approved empagliflozin (Jardiance, Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes. Jardiance is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).

Highlights of what executives from Aetna, Cigna and Humana told Managed Healthcare Executive

Growth of accountable care organizations across the U.S. healthcare market is gaining momentum

Pregnant women given pertussis vaccination in their third trimester to prevent infections in newborns, should be reassured that the vaccine is safe, and in fact, may be beneficial, according to a study published in The BMJ online July 11, 2014.

FDA has approved olodaterol (Striverdi Respimat, Boehringer Ingelheim) Inhalation Spray 5 µg as a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

The American Academy of Pediatrics (AAP) revision of its recommendations for use of palivizumab (Synagis, MedImmune Specialty Care Division of AstraZeneca) for respiratory syncytial virus (RSV) in infants has fueled a reaction from the drug’s manufacturer.